Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US
This study characterizes real-world treatment patterns and economic and healthcare resource utilization (HCRU) burden associated with first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) without actionable alterations in the United States. This retrospective observational study...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342013717086208 |
|---|---|
| author | Divyan Chopra David M. Waterhouse Ihtisham Sultan Björn Stollenwerk |
| author_facet | Divyan Chopra David M. Waterhouse Ihtisham Sultan Björn Stollenwerk |
| author_sort | Divyan Chopra |
| collection | DOAJ |
| description | This study characterizes real-world treatment patterns and economic and healthcare resource utilization (HCRU) burden associated with first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) without actionable alterations in the United States. This retrospective observational study used Optum Clinformatics<sup>®</sup> data. A total of 15,659 patients with metastatic NSCLC who started 1L treatment between January 2020 and March 2023 were included (52% male; mean age at the start of 1L treatment 71.7 years; 86% Medicare Advantage). The most frequent 1L regimens were immune checkpoint inhibitor (ICI) + platinum-based chemotherapy (PBCT) (47%), PBCT only (26%), and ICI only (20%). The median 1L treatment duration was 4.2 months (range 2.7–6.5) and was shorter with chemotherapy-only regimens. Outpatient visits accounted for the majority of HCRU (mean 6.6 visits per patient per month [PPPM]). Outpatient, inpatient, and emergency department visits were highest for chemotherapy-only regimens. Mean total (all-cause) healthcare costs were $32,215 PPPM and were highest for ICI + chemotherapy ($34,741–38,454 PPPM). Inpatient costs PPPM were highest for PBCT ($4725) and ICI + non-PBCT ($4648). First-line treatment of metastatic NSCLC without actionable alterations imposes a notable HCRU and cost burden, underscoring the need for better treatment options to improve outcomes and reduce economic impact. |
| format | Article |
| id | doaj-art-d9e70e6d5ab84240a7724c6b93eaaacb |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-d9e70e6d5ab84240a7724c6b93eaaacb2025-08-20T03:43:30ZengMDPI AGCurrent Oncology1198-00521718-77292025-03-0132315110.3390/curroncol32030151Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the USDivyan Chopra0David M. Waterhouse1Ihtisham Sultan2Björn Stollenwerk3Amgen, Thousand Oaks, CA 91320, USAOHC (Oncology Hematology Care), Cincinnati, OH 45242, USAAmgen, Thousand Oaks, CA 91320, USAAmgen (EUROPE) GmbH, 6343 Rotkreuz, SwitzerlandThis study characterizes real-world treatment patterns and economic and healthcare resource utilization (HCRU) burden associated with first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) without actionable alterations in the United States. This retrospective observational study used Optum Clinformatics<sup>®</sup> data. A total of 15,659 patients with metastatic NSCLC who started 1L treatment between January 2020 and March 2023 were included (52% male; mean age at the start of 1L treatment 71.7 years; 86% Medicare Advantage). The most frequent 1L regimens were immune checkpoint inhibitor (ICI) + platinum-based chemotherapy (PBCT) (47%), PBCT only (26%), and ICI only (20%). The median 1L treatment duration was 4.2 months (range 2.7–6.5) and was shorter with chemotherapy-only regimens. Outpatient visits accounted for the majority of HCRU (mean 6.6 visits per patient per month [PPPM]). Outpatient, inpatient, and emergency department visits were highest for chemotherapy-only regimens. Mean total (all-cause) healthcare costs were $32,215 PPPM and were highest for ICI + chemotherapy ($34,741–38,454 PPPM). Inpatient costs PPPM were highest for PBCT ($4725) and ICI + non-PBCT ($4648). First-line treatment of metastatic NSCLC without actionable alterations imposes a notable HCRU and cost burden, underscoring the need for better treatment options to improve outcomes and reduce economic impact.https://www.mdpi.com/1718-7729/32/3/151economic burdenimmunotherapychemotherapyobservationalclaims data |
| spellingShingle | Divyan Chopra David M. Waterhouse Ihtisham Sultan Björn Stollenwerk Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US Current Oncology economic burden immunotherapy chemotherapy observational claims data |
| title | Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US |
| title_full | Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US |
| title_fullStr | Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US |
| title_full_unstemmed | Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US |
| title_short | Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US |
| title_sort | real world treatment patterns healthcare resource utilization and healthcare costs in the first line treatment of metastatic non small cell lung cancer in the us |
| topic | economic burden immunotherapy chemotherapy observational claims data |
| url | https://www.mdpi.com/1718-7729/32/3/151 |
| work_keys_str_mv | AT divyanchopra realworldtreatmentpatternshealthcareresourceutilizationandhealthcarecostsinthefirstlinetreatmentofmetastaticnonsmallcelllungcancerintheus AT davidmwaterhouse realworldtreatmentpatternshealthcareresourceutilizationandhealthcarecostsinthefirstlinetreatmentofmetastaticnonsmallcelllungcancerintheus AT ihtishamsultan realworldtreatmentpatternshealthcareresourceutilizationandhealthcarecostsinthefirstlinetreatmentofmetastaticnonsmallcelllungcancerintheus AT bjornstollenwerk realworldtreatmentpatternshealthcareresourceutilizationandhealthcarecostsinthefirstlinetreatmentofmetastaticnonsmallcelllungcancerintheus |